Tag: Advocacy

For those of us in the Northern Hemisphere, spring is here. This is a time of renewal and hope for better times ahead, echoing what our field is trying to achieve: the rejuvenation of aging cells and tissues to keep older people free from age-related diseases. On that note, let’s take a look at what...

João Pedro de Magalhães, professor at the University of Birmingham, is known as a prominent geroscientist who has been in the field forever, enriching it with top-tier research. He is also a skilled longevity advocate who has long taken interest in the ethics of longevity, first offering his perspective as far back as 2003. Prof....

The last installment in our end-of-year series of expert roundups might be the least flashy, but it is arguably no less important than the previous ones dedicated to longevity biotech and geroscience. Public advocacy is a powerful lever. To quote Abraham Lincoln: “Public sentiment is everything. With it, nothing can fail; against it, nothing can...

Happy holidays! Winter is in full swing for those of us in the Northern Hemisphere. It is a time for cozy nights by the fire and a great time to catch up on what has been happening at Lifespan News and LRI. A cultural intelligence platform for effective advocacy We are delighted to announce that...

The idea of living longer, healthier lives thanks to rejuvenation biotechnology has steadily become more common. Gradually increasing numbers of articles are discussing this idea, especially as science is starting to catch up and may eventually even deliver on it. With that in mind, I was pleasantly surprised this week to be greeted by an...

To challenge cultural stereotypes and misconceptions about longevity, a new organization aims to engage people who create culture. Its list of “cultural ambassadors" includes Oscar- and Grammy-winning artists. Reframing the case for longevity Even as geroscience is becoming a respected field, producing breakthroughs and spawning dozens of startups, the public’s attitudes toward longevity still largely...